Clinical pharmacology and pharmacogenetics of gemcitabine

Drug Metab Rev. 2009;41(2):77-88. doi: 10.1080/03602530902741828.

Abstract

Gemcitabine is a cytotoxic nucleoside analog, which is widely used in the treatment of malignancies. Interindividual differences in gemcitabine pharmacokinetics and pharmacodynamics have been demonstrated. Pharmacogenetic factors may account for a significant proportion of these differences. This review provides an update on the pharmacogenetics of gemcitabine and its influence on gemcitabine efficacy and toxicity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antimetabolites, Antineoplastic* / pharmacokinetics
  • Antimetabolites, Antineoplastic* / pharmacology
  • Antimetabolites, Antineoplastic* / toxicity
  • Cytidine Deaminase / genetics
  • Cytidine Deaminase / metabolism
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacokinetics
  • Deoxycytidine / pharmacology
  • Deoxycytidine / toxicity
  • Deoxycytidine Kinase / genetics
  • Deoxycytidine Kinase / metabolism
  • Ethnic Groups / genetics
  • Humans
  • Nucleoside Transport Proteins / genetics
  • Nucleoside Transport Proteins / metabolism
  • Nucleotidases / genetics
  • Nucleotidases / metabolism
  • Pharmacogenetics*
  • Polymorphism, Genetic
  • Ribonucleotide Reductases / genetics
  • Ribonucleotide Reductases / metabolism

Substances

  • Antimetabolites, Antineoplastic
  • Nucleoside Transport Proteins
  • Deoxycytidine
  • gemcitabine
  • Ribonucleotide Reductases
  • Deoxycytidine Kinase
  • Nucleotidases
  • Cytidine Deaminase